Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma Academic Article uri icon

Overview

MeSH Major

  • Cisplatin
  • Drug Resistance, Neoplasm
  • Mutation
  • Urologic Neoplasms
  • Urothelium
  • Xeroderma Pigmentosum Group D Protein

abstract

  • Somatic ERCC2 mutations correlate with complete response to cisplatin-based chemosensitivity in muscle-invasive urothelial carcinoma, and clinically identified mutations lead to cisplatin sensitivity in vitro. Nucleotide excision repair pathway defects may drive exceptional response to conventional chemotherapy.

authors

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4238969

Digital Object Identifier (DOI)

  • 10.1158/2159-8290.CD-14-0623

PubMed ID

  • 25096233

Additional Document Info

start page

  • 1140

end page

  • 53

volume

  • 4

number

  • 10